Nurse practitioner Beth Faiman provides insights into the essential nursing strategies for monitoring, assessing, and handling toxicities associated with talquetamab in multiple myeloma patients. Talquetamab, also known as Talvey, is a bispecific antibody approved by the FDA for treating multiple myeloma after the failure of four or more prior lines of therapy. Faiman emphasizes the importance of monitoring for cytokine release syndrome, neurotoxicity, and managing dermatologic and oral toxicities to support patients effectively during their treatment with talquetamab.
Patients undergoing treatment with talquetamab often require hospital admission for close monitoring, especially during the initial step-up dosing phase to detect early toxicities like cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome (ICANS). Nurses play a crucial role in assessing patients using specific tools that evaluate cognitive changes, handwriting, and early neurologic symptoms. Additionally, close monitoring for short-term infections is essential during the step-up phase of talquetamab treatment to ensure patient safety and well-being.
Apart from acute effects, nurses need to be vigilant about dermatologic and oral toxicities linked to the expression of GPRC5D on keratinized and oral cells. Patients may experience dry skin, nail thinning, peeling, and itchiness, necessitating interventions such as moisturizers, antihistamines, topical steroids, nail care, antifungals, and oral rinses. Adjusting dosage or modifying treatment schedules may be necessary to strike a balance between disease control and patient tolerability, thereby ensuring continuity of therapy.
Dermatologic adverse events are a notable concern in the early stages of talquetamab treatment, with patients experiencing skin issues like dryness, rash, and peeling. Recommendations include the use of heavy moisturizers, nail hardeners, topical vitamin E oil, and triamcinolone to manage these skin toxicities effectively. Nurses should educate patients on the potential side effects and the appropriate interventions to alleviate discomfort and promote adherence to treatment.
Oral toxicities associated with talquetamab treatment typically manifest weeks into therapy, presenting symptoms such as taste changes, dry mouth, and difficulty swallowing. Nurses should conduct thorough oral assessments to identify issues like thrush and provide suitable interventions such as oral rinses with dexamethasone or antifungal medications as needed. Continuous monitoring and proactive management of oral toxicities are crucial to enhance patient comfort and compliance with the treatment regimen.
To address persistent oral toxicities, a personalized approach to talquetamab dosing may be necessary. Adjusting the dosing frequency based on individual patient tolerability and response to treatment can help mitigate adverse effects while maintaining therapeutic efficacy. By closely monitoring patients’ progress and adjusting treatment regimens as needed, nurses can optimize patient outcomes and ensure long-term adherence to talquetamab therapy for better disease management.
In conclusion, effective nursing management of talquetamab toxicities in multiple myeloma patients is pivotal for enhancing treatment outcomes and patient quality of life. Through diligent monitoring, timely intervention, and personalized care strategies, nurses can mitigate the impact of toxicities, improve patient comfort, and promote treatment adherence. By staying informed about the latest research and collaborating with healthcare teams, nurses play a vital role in optimizing the care and support provided to patients undergoing talquetamab therapy, ultimately contributing to better treatment outcomes and overall patient well-being.
Key Takeaways:
– Nurses play a crucial role in monitoring and managing talquetamab toxicities in multiple myeloma patients, focusing on cytokine release syndrome, neurotoxicity, dermatologic, and oral side effects.
– Close monitoring during the initial treatment phases is essential to detect early toxicities and ensure patient safety.
– Personalized dosing adjustments and proactive management of toxicities can help optimize patient outcomes and treatment adherence.
– Collaboration with healthcare teams, patient education, and continuous monitoring are key to enhancing patient comfort and treatment efficacy during talquetamab therapy.
Tags: clinical trials
Read more on oncnursingnews.com